Acorda Therapeutics Competitors and Similar CompaniesClear all

Acorda Therapeutics's competitors and similar companies include AMAG Pharmaceuticals, Kartos Therapeutics, VCANBIO and Codiak Biosciences.

	Acorda Therapeutics Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.	AMAG Pharmaceuticals AMAG Pharmaceuticals is a pharmaceutical company that develops and delivers medicines across a range of therapeutic areas.	Kartos Therapeutics Kartos Therapeutics is a clinical-stage biopharmaceutical company.	VCANBIO VCANBIO Cell & Gene Engineering (also known as Zhongyuan Union) is a biotech company that offers health management services and products.	Codiak Biosciences Codiak Biosciences is a biopharmaceutical company focused on the development of exosome-based therapeutics.
Founding Date	Founding Date 1995	Founding Date 1981	Founding Date 2018	Founding Date 1993	Founding Date 2015
Type	Type Public	Type Subsidiary	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech therapy	Tags Healthcare clinical research drug development pharma women's health	Tags Healthcare biotech therapy	Tags Healthcare biotech medical diagnostics platform therapy	Tags Healthcare biotech therapy
Locations	Locations Ardsley, US HQ Chelsea, US South San Francisco, US Waltham, US	Locations Waltham, US HQ	Locations Redwood City, US HQ	Locations Tianjin, CN HQ	Locations Cambridge, US HQ
Employees	Employees 4742% decrease	Employees 3751% decrease	Employees 677% decrease	Employees 2,0149% decrease	Employees 992% decrease
Valuation ($)	Valuation ($) 821 k	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 1.4 b	Valuation ($) 2.8 m
Financial
Revenue (est.)	Revenue (est.) $117.6m (FY, 2023)	Revenue (est.) $327.8m (FY, 2019)	Revenue (est.) N/A	Revenue (est.) ¥1.4b (FY, 2025)	Revenue (est.) $22.9m (FY, 2021)
Cost of goods	Cost of goods $15.3m (FY, 2023)	Cost of goods $107.2m (FY, 2019)	Cost of goods N/A	Cost of goods ¥438.8m (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit ($106.9m) (FY, 2019)	Gross profit N/A	Gross profit ¥993.4m (FY, 2025)	Gross profit N/A
Net income	Net income ($252.9m) (FY, 2023)	Net income ($466.5m) (FY, 2019)	Net income N/A	Net income ¥103.5m (FY, 2025)	Net income ($37.2m) (FY, 2021)
Operating ⚠
Products	Products N/A	Products 4 (FY, 2019)	Products N/A	Products N/A	Products 11 (Q2, 2020)